Bradycardia Treatment
PreclinicalSmall molecule
Bradycardia Treatment is one of 8 small molecule programs targeting Nerve Block. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Nerve Block
#DrugCompanyPhaseTrials
1Liposomal Bupivacaine
TTLC Biopharmaceuticals, Inc.
Phase 3
Intranasal Ketorolac Tromethamine
TTehran University of Medical Sciences
Phase 3
Esmeron
Merck & Co.Preclinical
Marcaine
UUniversity of Chicago
Phase 1
Bupivacain
IIstanbul University
Preclinical
Tegileridine
XXin Chen
Preclinical
Tetracaine Hydrochloride
BBausch Health Americas, Inc.
Preclinical
Bradycardia Treatment
DDaping Hospital and the Research Institute of Surgery of the Third Military Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Nerve Block1 trial
Cervical Vagus Nerve Block Prevents Ocularvagal Reflex
Unknown status·—·N/A·NCT04950881·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bradycardia Treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details